Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

iTeos Therapeutics, Inc.

$10.15

+0.01 (+0.1%)

D 37Pipeline Score Fair Value Biotech · Clinical
Market Cap
448.68 M
EPS
-4.85
P/E Ratio
-
Value Trade
111.74 M
-0.29 %
Week
0 %
1 Month
0.89 %
3 Month
46.46 %
6 Month
-65.71 %
5 Year
-60.27 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
11.01 M
52 Week Range
4.80 - 17.63
% held by Insiders
6.26 %
% held by Institutions
116.32 %
Enterprise Value
-61.62 M
Total Shares
44.21 M
Short %
7.53 %
Float Shares
42.71 M
Company Description
Founded:24-07-2020

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2025-04-25
EOS-215 (first-in-class TREM2 antagonist)
Data readout
Pre-clinical
—
–
–
–
2025-04-25
EOS-215 (first-in-class TREM2 antagonist)
Data readout
Pre-clinical
—
–
–
–
2025-04-25
EOS-215 (first-in-class TREM2 antagonist)
Data readout
Pre-clinical
—
–
–
–
Unlock 4 more historical catalysts
Drug Pipeline Intelligence
D37
Pipeline Score
$351M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
0.8x
rNPV / MCap
Top 54%
Micro Cap
(rank 426 of 923)
Percentile Rank
iTeos Therapeutics, Inc. faces pipeline headwinds (37/100), with $1.5B risk-adjusted pipeline value, led by inupadenant in Metastatic NSCLC - Non-Small Cell Lung Cancer (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
inupadenant
Small molecule		Metastatic NSCLC - Non-Small Cell Lung CancerPhase 2NCT0540338510% $1.0B ACTIVE NOT_RECRUITING 36 SLOW B (73) Oct 1, 2025 -LOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
belrestotug
non-small cell lung cancer
Phase 2
2025-05-13

did not meet established criteria for clinically meaningful improvements in progression free survival

Read More

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Read More
belrestotug
non-small cell lung cancer
Phase 2
2025-05-13

did not meet established criteria for clinically meaningful improvements in progression free survival

Read More

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Read More
belrestotug
non-small cell lung cancer
Phase 2
2025-05-13

did not meet established criteria for clinically meaningful improvements in progression free survival

Read More

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ITOS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
ITOS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ITOS ranks across every disease it competes in
Competitive Position is a premium feature
See how ITOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial